Sarepta demanded Duchenne patient advocacy group censor video critical of the company

Taking stock of the drug industry, from the lab to the medicine chest

July 29, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Kristoffer Tripplaar/Sipa via AP STAT+ | Sarepta demanded Duchenne patient advocacy group censor video critical of the company The incident involving Parent Project Muscular Dystrophy raises questions about whether Sarepta seeks to muzzle debate over its Duchenne medicines. By Adam Feuerstein Opinion: Mark Cuban's company won't fix drug costs, but it can still help rectify America's drug shortages First Opinion: Experts hail Mark Cuban for good intentions, but say his biggest impact can be as a drug manufacturer, not cost-plus drug wholesaler. By Ezekiel J. Emanuel and John Connolly Opinion: Survey: Neurologists split on prescribing new Alzheimer's treatments Neurologists' beliefs in the effectiveness or hazards of anti-amyloid drugs for Alzheimer's will affect whether their patients get them. By P. Murali Doraiswamy and Lon S. Schneider Adobe STAT+ | In a big step for liquid biopsy, FDA approves a blood screening test for colorectal cancer Colon cancer is the second-most diagnosed cancer in the U.S. and the second-leading cause of cancer death. By Matthew Herper

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser